Accelero Reports 2020 Financial Results and 2021 Forecast
Accelero Bioanalytics GmbH (“Accelero”) announced key figures for the fiscal year 2020 in Germany´s Federal Gazette.
News
Accelero Receives EU Eurostars Funding Supporting a Gene Therapy for the Treatment of Lypodystrophy
Accelero Bioanalytics GmbH (“Accelero”) is awarded EUR 136,500 in project grants to support research and development of a gene therapy targeting lypodystrophy.
Accelero Receives Authority Permit for SARS-CoV-2 Testing
Accelero Bioanalytics GmbH (“Accelero”) has received the authority permit for processing and analysis of SARS-CoV-2 in biological samples.
Accelero Signs Service Agreement for AAV-Based Gene Therapy Development
Accelero Bioanalytics GmbH (“Accelero”) signed an agreement with the gene therapy company CombiGene AB, Lund, Sweden (“CombiGene”) to support the non-clinical development of an Adeno-associated virus (AAV) with its bioanalytical and regulatory expertise.
Accelero Sustaining Member of the CONELIS Competence Network Life Science
Accelero is pleased to announce that the company has been selected as a sustaining member of the CONELIS network life science. The CONELIS network accumulates top-class consulting services for the biotechnology and pharmaceutical industry.
Accelero Participates in TRAIN-HEART Marie Curie Program Discovering RNA Therapeutics for Heart Failure
Accelero is pleased to announce that the company participates as a partner organization in the Marie Curie TRAIN-HEART consortium funded by the European Commission.
GLP Certificate Refreshed on 15 March 2019
Accelero Bioanalytics GmbH, a Berlin-based GLP certified bioanalytical service provider, announces today that the GLP certificate first issued in 2016 has now been renewed by the competent authority for another three years. The re-inspection has been conducted in November 2018.
Accelero Initiates Clinical Study to Collect Human Wound Fluid
The company is pleased to initiate its first formal clinical study at one of the breast cancer centres in Berlin, Germany. The study is entitled “Post-operative wound fluid collected from female breast cancer patients” and has been approved by the clinical ethics committee.
Accelero Launches Complementary Website
Acccelero Bioanalytics GmbH, a GLP certified contract research laboratory in Berlin, Germany, announces today the publication of the supplementary website binding-assay.com.
Accelero Sees 23% Sales Revenue Increase in 2017 - 9% Operating Profit Margin
Accelero Bioanalytics GmbH is a GLP certified contract research service provider for regulatory drug development, and maintains biosafety level 2 laboratories in compliance with ICH GCP regulations.
Contact
Office and Management:
Accelerō® Bioanalytics GmbH
Schulzestrasse 20
13187 Berlin
GERMANY
| +49 30 610 910 300 (Office) | |
| service(at)accelero-bioanalytics.com |